1. Home
  2. BCHT vs SER Comparison

BCHT vs SER Comparison

Compare BCHT & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birchtech Corp. Common Stock

BCHT

Birchtech Corp. Common Stock

N/A

Current Price

$1.35

Market Cap

36.6M

Sector

Industrials

ML Signal

N/A

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$2.74

Market Cap

42.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCHT
SER
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.6M
42.0M
IPO Year
2016
2024

Fundamental Metrics

Financial Performance
Metric
BCHT
SER
Price
$1.35
$2.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$15.00
$15.00
AVG Volume (30 Days)
71.9K
54.5K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,626,366.00
$130,000.00
Revenue This Year
$13.42
N/A
Revenue Next Year
$61.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.26
132.14
52 Week Low
$1.26
$1.22
52 Week High
$2.48
$7.92

Technical Indicators

Market Signals
Indicator
BCHT
SER
Relative Strength Index (RSI) 40.50 63.48
Support Level $1.26 $1.69
Resistance Level $1.54 $3.16
Average True Range (ATR) 0.10 0.21
MACD 0.02 0.01
Stochastic Oscillator 28.57 78.75

Price Performance

Historical Comparison
BCHT
SER

About BCHT Birchtech Corp. Common Stock

Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: